Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Third-party virus-specific T-cells for the treatment of refractory viral infections

Michael Keller • 24 Apr 2022
The 2022 Tandem Meetings
General

Michael Keller, MD, Children’s National Health System, Washington, DC, gives an overview of the results of a study evaluating third-party virus-specific T-cell therapy for the treatment of different types of viral infections post-bone marrow transplant (BMT). The study reported an overall response rate (ORR) of 65% and in addition, responders demonstrated immune reconstitution against the viruses that were targeted. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Michael Keller

1:56
Advances in off-the-shelf third-party T-cells for the treatment of infectious diseases post-BMT
Michael Keller • 23 Apr 2022
1:05
Third-party virus-specific T-cells targeting 6 viruses post-BMT
Michael Keller • 23 Apr 2022

Related Videos

4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals